Insights

Can Clinical Trials Negate Patentability for Pharma Inventions?

Recent Decisions and FTC Challenges Dictate Caution When Listing Patents in the Orange Book

The Not-So-Safe Harbor for Research Tools: Lessons From the District of Delaware

Should the Experimental Use Exception Be Broadened?

Duty of Disclosure and Consistency Requirements for Statements to PTO and Other Government Agencies

The Final Word on an Alleged Infringer’s Intent in a Hatch-Waxman Safe Harbor Analysis

Federal Circuit Reiterates That an Alleged Infringer’s Intent Is Irrelevant in a Hatch-Waxman Safe Harbor Analysis

Federal Circuit to Consider the Relevance of an Alleged Infringer’s “Intent” in a Hatch-Waxman Safe Harbor Analysis